Gc-MAF

From Wikipedia, the free encyclopedia

Gc-MAF or Gc protein-derived macrophage activating factor is a functional change in the Gc protein (Vitamin D-binding protein) caused by serial deglycosylation. Gc-MAF is extremely potent and will at very low concentrations activate, regulate and expand macrophages. A Macrophage Activating Factor (MAF) is a lymphokine that primes macrophages to become cytotoxic to tumors. It also controls the expression of Ia antigens on the macrophage cell surface.[1]

Labeled as a 100% cure for some cancers, the methods of research conducted have been called into question and claims of this have been deemed misleading.[2]

History

In 1999 Nobuto Yamamoto published his first report mentioning the use of Gc-MAF on Tumor Bearing Mice.[3]

The first report of the application of Gc-MAF in research on humans dates back to the same year by another research group.

Yamamoto has used Gc-MAF as a treatment for human prostate cancer patients.[4]

References

  1. ↑ Mosser DM (February 2003). "The many faces of macrophage activation". J. Leukoc. Biol. 73 (2): 209–12. doi:10.1189/jlb.0602325. PMID 12554797. 
  2. ↑ ""Cancer cured for good?" – Gc-MAF and the miracle cure - Cancer Research UK - Science Update blog". Scienceblog.cancerresearchuk.org. Retrieved 2013-06-16. 
  3. ↑ Yoshihiko Koga, Venkateswara R. Naraparaju & Nobuto Yamamoto (1999) Wiley online Library doi:10.1046/j.1525-1373.1999.d01-3.x
  4. ↑ Yamamoto N, Suyama H, Yamamoto N (2008). "Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF" ([PDF]). TRANSLATIONAL ONCOLOGY 1 (2): 65–72. PMC 2510818. PMID 18633461. 
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.